Recent News

• 03.30.2026 - Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
• 03.24.2026 - Zymeworks Announces Participation in Upcoming Investor Conferences
• 03.18.2026 - Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
• 03.17.2026 - Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
• 03.02.2026 - Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
• 03.02.2026 - Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• 02.12.2026 - Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
• 01.27.2026 - Zymeworks Announces Participation in Upcoming Investor Conferences

Recent Filings

• 03.06.2026 - 144 Report of proposed sale of securities
• 03.02.2026 - EX-99.1 EX-99.1
• 03.02.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 03.02.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.02.2026 - 8-K Current report
• 03.02.2026 - EX-99.1 EX-99.1
• 03.02.2026 - 8-K Current report
• 02.17.2026 - 144 Report of proposed sale of securities
• 02.13.2026 - 144 Report of proposed sale of securities
• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors